Reuters logo
BRIEF-Lilly, Astrazeneca to develop potentially disease-modifying Alzheimer's treatment
December 9, 2016 / 12:23 PM / a year ago

BRIEF-Lilly, Astrazeneca to develop potentially disease-modifying Alzheimer's treatment

Dec 9 (Reuters) - Eli Lilly And Co

* Lilly and Astrazeneca to develop second potentially disease-modifying treatment for Alzheimer’s disease

* Will recognize upfront of $30 million (pretax), or approximately $0.02 per share (after-tax), as a charge to earnings in Q4 of 2016

* Worldwide agreement to co-develop MEDI1814, an antibody selective for amyloid-beta 42

* Under terms of new agreement, Lilly will make a $30 million upfront payment to Astrazeneca Source text for Eikon: Further company coverage: (Bangalore.newsroom@thomsonreuters.com)

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below